Showing results (41-50 of 95) with videos related to
Sort By:
Pageof 10
Biomaterials|December 29, 2004
In vitro degradation of silk fibroinRebecca L Horan, Kathryn Antle, Adam L Collette, et al.Tissue Engineering|May 24, 2007
Monitoring mesenchymal stromal cell developmental stage to apply on-time mechanical stimulation for ligament tissue engineeringJingsong Chen, Rebecca L Horan, Diah Bramono, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer StudyG Blijham, T Wagener, J Wils, et al.British Journal of Cancer|March 20, 2003
External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patientsY Vergouwe, E W Steyerberg, R de Wit, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary groupS D Fosså, P H Slee, M Brausi, et al.British Journal of Cancer|September 22, 1998
Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of CancerR de Wit, G Stoter, D T Sleijfer, et al.European Journal of Cancer (Oxford, England : 1990)|February 23, 2002
Statistical methodology of phase III cancer clinical trials: advances and future perspectivesR Sylvester, M Van Glabbeke, L Collette, et al.Scandinavian Journal of Urology|January 10, 2019
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonistE David Crawford, B Tombal, T Keane, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 19, 2010
Tailored follow-up for early breast cancer patients: a prognostic index that predicts locoregional recurrenceJ G H van Nes, H Putter, M van Hezewijk, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001T M Churilla, E Handorf, S Collette, et al.Pageof 10